



Clinical trial results:

An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or CD30-positive cutaneous T-cell lymphoma

Summary

EudraCT number	2010-020363-21
Trial protocol	FR GB HU CZ ES IT BG BE DE
Global end of trial date	21 August 2020

Results information

Result version number	v1 (current)
This version publication date	06 September 2021
First version publication date	06 September 2021

Trial information

Trial identification

Sponsor protocol code	SGN35-010
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01196208
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Seagen Inc.
Sponsor organisation address	21823 30th Drive S.E., Bothell, United States, 98021
Public contact	Regulatory Affairs, PSI CRO Hungary Pharma Support LLC, +36 1555 6755, rabudapest@psi-cro.com
Scientific contact	Regulatory Affairs, PSI CRO Hungary Pharma Support LLC, +36 1555 6755, rabudapest@psi-cro.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 December 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 August 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

- To provide the option of treatment with brentuximab vedotin for patients in study SGN35-005 who experience progression of Hodgkin lymphoma (HL), and for those patients in study C25001 on the experimental arm with an objective response at the time of discontinuation of brentuximab vedotin or the control arm who experience progression of CD30- positive (CD30+) cutaneous Tcell lymphoma (CTCL) per independent review facility (IRF).
- To assess the safety and tolerability of brentuximab vedotin
- In the US only, to provide access to brentuximab vedotin for patients with relapsed or refractory HL and patients with relapsed or refractory anaplastic large cell lymphoma (ALCL) (Amendment 5 and later, not applicable).

Protection of trial subjects:

This study was conducted in accordance with applicable regulations/guidelines set forth by the Food and Drug Administration (FDA) in 21 CFR Parts 11, 50, 54, 56, and 312; the European Union (EU) Directive 2001/20/EC and 2005/28/EC; and with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. Essential documents are retained in accordance with ICH GCP.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 September 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 14
Country: Number of subjects enrolled	Romania: 5
Country: Number of subjects enrolled	Spain: 4
Country: Number of subjects enrolled	United Kingdom: 22
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Hungary: 5
Country: Number of subjects enrolled	Italy: 5
Country: Number of subjects enrolled	United States: 288
Country: Number of subjects enrolled	Serbia: 5
Country: Number of subjects enrolled	Switzerland: 2
Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	Russian Federation: 15

Worldwide total number of subjects	377
EEA total number of subjects	40

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	3
Adolescents (12-17 years)	3
Adults (18-64 years)	329
From 65 to 84 years	41
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

First participant enrolled: 03-Sep-2010

Pre-assignment

Screening details:

Participants were screened for eligibility prior to enrollment.

Period 1

Period 1 title	Enrollment
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All Enrolled
-----------	--------------

Arm description:

Includes all enrolled participants (including multiple enrollment instances per participant).

Arm type	Expanded Access
Investigational medicinal product name	brentuximab vedotin
Investigational medicinal product code	
Other name	ADCETRIS
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Brentuximab vedotin, 1.2 mg/kg or 1.8 mg/kg via intravenous infusion every 3 weeks. Participants in this study may have received brentuximab vedotin (SGN-35) for up to 16 treatment cycles as long as, in the investigator's judgment, they continued to experience a clinical benefit.

Number of subjects in period 1	All Enrolled
Started	377
Completed	363
Not completed	14
Repeat enrollment	14

Period 2

Period 2 title	Treatment
Is this the baseline period?	Yes ^[1]
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All Treated
------------------	-------------

Arm description:

Every participant is only counted once, with the data from the first enrollment used for the summary.

Arm type	Experimental
Investigational medicinal product name	brentuximab vedotin
Investigational medicinal product code	
Other name	ADCETRIS
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Brentuximab vedotin, 1.2 mg/kg or 1.8 mg/kg via intravenous infusion every 3 weeks. Participants in this study may have received brentuximab vedotin (SGN-35) for up to 16 treatment cycles as long as, in the investigator's judgment, they continued to experience a clinical benefit.

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: Period 1 includes multiple enrollments per individual.

Number of subjects in period 2^[2]	All Treated
Started	363
Completed	338
Not completed	25
Adverse event, serious fatal	16
Consent withdrawn by subject	5
Unspecified	3
Lost to follow-up	1

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Worldwide enrollment includes multiple enrollments per individual.

Baseline characteristics

Reporting groups

Reporting group title	Treatment
Reporting group description: -	

Reporting group values	Treatment	Total	
Number of subjects	363	363	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	39.7		
standard deviation	± 16.26	-	
Gender categorical			
Units: Subjects			
Female	166	166	
Male	197	197	
Race			
Units: Subjects			
American Indian or Alaska Native	1	1	
Asian	9	9	
Black or African American	26	26	
Native Hawaiian or Other Pacific Islander	1	1	
White	311	311	
Other	13	13	
Not Reported	2	2	
Ethnicity			
Units: Subjects			
Hispanic or Latino	22	22	
Not Hispanic or Latino	333	333	
Not Reported	8	8	

End points

End points reporting groups

Reporting group title	All Enrolled
Reporting group description: Includes all enrolled participants (including multiple enrollment instances per participant).	
Reporting group title	All Treated
Reporting group description: Every participant is only counted once, with the data from the first enrollment used for the summary.	
Subject analysis set title	Safety Analysis Set
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: All treatment instances (multiple enrollment instances are captured per individual).	

Primary: Overall Summary of Incidence of Treatment-Emergent Adverse Events, Serious Adverse Events and Deaths

End point title	Overall Summary of Incidence of Treatment-Emergent Adverse Events, Serious Adverse Events and Deaths ^[1]
End point description: The primary objectives of the study were to provide expanded access brentuximab vedotin to subjects for a maximum of 16 cycles and to assess the safety of brentuximab vedotin. No new safety concerns were identified in the study.	
End point type	Primary
End point timeframe: Duration of study	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There was no predetermined sample size required for statistical analyses. Descriptive statistical analysis of subject disposition, baseline characteristics, exposure to study drug, and AEs was performed.

End point values	Safety Analysis Set			
Subject group type	Subject analysis set			
Number of subjects analysed	376			
Units: Participants				
Treatment-emergent adverse events (TEAEs)	345			
TEAEs with CTCAE Grade 3 or higher	132			
TEAEs related to the study drug	273			
TEAEs unrelated to the study drug	291			
TEAEs causing dose delay	58			
TEAEs causing infusion stop or interruption	17			
TEAEs causing unplanned dose adjustment	18			
Serious adverse events (SAEs)	73			
Serious TEAEs	71			
Serious TEAEs related to the study drug	25			
Serious TEAEs unrelated to the study drug	55			
AEs leading to study discontinuation	107			

AEs leading to the study drug discontinuation	93			
Deaths	23			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the date of the first dose of study medication to the date of the last dose of the study medication plus 21 days. Some SAEs occurred prior to the first dose of the study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	13.0

Reporting groups

Reporting group title	Safety Analysis Set
-----------------------	---------------------

Reporting group description:

Data is summarized on a treatment episode level. Each time a patient is enrolled in the study will be counted separately

Serious adverse events	Safety Analysis Set		
Total subjects affected by serious adverse events			
subjects affected / exposed	73 / 376 (19.41%)		
number of deaths (all causes)	23		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anaplastic large cell lymphoma T- and null-cell types			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anaplastic large cell lymphoma T- and null-cell types recurrent			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hodgkin's disease			
subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 3		
Hodgkin's disease recurrent			

subjects affected / exposed	3 / 376 (0.80%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 3		
Malignant neoplasm progression			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Mycosis fungoides			
subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	1 / 1		
Neoplasm progression			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Tumour pain			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Multi-organ failure			
subjects affected / exposed	3 / 376 (0.80%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 5		
Pain			
subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		

Pyrexia			
subjects affected / exposed	5 / 376 (1.33%)		
occurrences causally related to treatment / all	2 / 7		
deaths causally related to treatment / all	0 / 0		
Sudden death			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Immune system disorders			
Acute graft versus host disease in intestine			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anaphylactic reaction			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Acute respiratory failure			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cough			

subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	5 / 376 (1.33%)		
occurrences causally related to treatment / all	1 / 7		
deaths causally related to treatment / all	0 / 0		
Eosinophilic pneumonia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haemothorax			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia aspiration			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Pneumothorax			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary haemorrhage			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Respiratory failure			
subjects affected / exposed	3 / 376 (0.80%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Investigations			
Blood bilirubin increased			

subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	3 / 6		
deaths causally related to treatment / all	0 / 0		
Positive Rombergism			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Femoral neck fracture			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vaccination complication			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Wound dehiscence			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial flutter			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		

Pericardial effusion			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sinus tachycardia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Supraventricular tachycardia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Neuropathy peripheral			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Reversible posterior leukoencephalopathy syndrome			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bone marrow granuloma			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Coagulopathy			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Neutropenia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	2 / 2		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Ascites			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Colitis			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	2 / 7		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			

subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal toxicity			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal perforation			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Neutropenic colitis			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Vomiting			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	7 / 7		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Rash erythematous			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Toxic skin eruption			

subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	2 / 376 (0.53%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bone pain			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc protrusion			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscular weakness			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Bronchopulmonary aspergillosis subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cellulitis subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Clostridial infection subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Device related infection subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Infection subjects affected / exposed	2 / 376 (0.53%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Influenza subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Meningitis aseptic subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peritonsillar abscess				

subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumocystis jiroveci pneumonia				
subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	12 / 376 (3.19%)			
occurrences causally related to treatment / all	5 / 16			
deaths causally related to treatment / all	2 / 7			
Pneumonia staphylococcal				
subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Progressive multifocal leukoencephalopathy				
subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	2 / 2			
Sepsis				
subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Staphylococcal infection				
subjects affected / exposed	1 / 376 (0.27%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Staphylococcal skin infection				

subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Syphilis			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Hypoalbuminaemia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	1 / 376 (0.27%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Safety Analysis Set		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	345 / 376 (91.76%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hodgkin's disease recurrent			
subjects affected / exposed	19 / 376 (5.05%)		
occurrences (all)	20		
Vascular disorders			
Hypertension			
subjects affected / exposed	20 / 376 (5.32%)		
occurrences (all)	21		
General disorders and administration			

site conditions			
Asthenia			
subjects affected / exposed	22 / 376 (5.85%)		
occurrences (all)	32		
Chills			
subjects affected / exposed	29 / 376 (7.71%)		
occurrences (all)	31		
Fatigue			
subjects affected / exposed	185 / 376 (49.20%)		
occurrences (all)	232		
Oedema peripheral			
subjects affected / exposed	27 / 376 (7.18%)		
occurrences (all)	31		
Pyrexia			
subjects affected / exposed	65 / 376 (17.29%)		
occurrences (all)	82		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	67 / 376 (17.82%)		
occurrences (all)	75		
Dyspnoea			
subjects affected / exposed	57 / 376 (15.16%)		
occurrences (all)	73		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	29 / 376 (7.71%)		
occurrences (all)	31		
Depression			
subjects affected / exposed	26 / 376 (6.91%)		
occurrences (all)	30		
Insomnia			
subjects affected / exposed	33 / 376 (8.78%)		
occurrences (all)	34		
Investigations			
Weight decreased			

subjects affected / exposed	23 / 376 (6.12%)		
occurrences (all)	27		
Nervous system disorders			
Dizziness			
subjects affected / exposed	24 / 376 (6.38%)		
occurrences (all)	26		
Headache			
subjects affected / exposed	33 / 376 (8.78%)		
occurrences (all)	38		
Neuropathy peripheral			
subjects affected / exposed	77 / 376 (20.48%)		
occurrences (all)	114		
Paraesthesia			
subjects affected / exposed	20 / 376 (5.32%)		
occurrences (all)	29		
Peripheral sensory neuropathy			
subjects affected / exposed	75 / 376 (19.95%)		
occurrences (all)	115		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	37 / 376 (9.84%)		
occurrences (all)	93		
Lymphadenopathy			
subjects affected / exposed	20 / 376 (5.32%)		
occurrences (all)	23		
Neutropenia			
subjects affected / exposed	20 / 376 (5.32%)		
occurrences (all)	35		
Thrombocytopenia			
subjects affected / exposed	21 / 376 (5.59%)		
occurrences (all)	49		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	26 / 376 (6.91%)		
occurrences (all)	29		
Constipation			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nausea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>43 / 376 (11.44%)</p> <p>48</p> <p>63 / 376 (16.76%)</p> <p>83</p> <p>104 / 376 (27.66%)</p> <p>135</p> <p>30 / 376 (7.98%)</p> <p>33</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>Alopecia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Night sweats</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pruritus</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Rash</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>34 / 376 (9.04%)</p> <p>34</p> <p>37 / 376 (9.84%)</p> <p>38</p> <p>65 / 376 (17.29%)</p> <p>77</p> <p>40 / 376 (10.64%)</p> <p>53</p>		
<p>Endocrine disorders</p> <p>Hypothyroidism</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>21 / 376 (5.59%)</p> <p>21</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Back pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Myalgia</p>	<p>32 / 376 (8.51%)</p> <p>42</p> <p>49 / 376 (13.03%)</p> <p>57</p>		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pain in extremity</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>21 / 376 (5.59%)</p> <p>31</p> <p>25 / 376 (6.65%)</p> <p>32</p>		
<p>Infections and infestations</p> <p>Upper respiratory tract infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>22 / 376 (5.85%)</p> <p>23</p>		
<p>Metabolism and nutrition disorders</p> <p>Decreased appetite</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>42 / 376 (11.17%)</p> <p>46</p>		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 December 2010	Reflects change from phase 2/3 to study with an expanded access program in the US that would include patients with ALCL and HL.
08 March 2011	Allows enrollment of some patients with prior allogenic SCT.
29 April 2011	Removes the requirement for prior autologous SCT.
03 October 2011	Includes physical examinations as a scheduled safety assessment at screening, at Day 1 of each treatment cycles, and at the EOT visit.
18 March 2013	Includes patients from study C35001 with CD-30-positive cutaneous T-cell lymphoma. Allows enrollment of patients who progressed while receiving treatment with methotrexate or bexarotene on the control arm of study C25001.
20 October 2014	Adds an additional study population so that a treatment option would be available for patients who were previously treated with brentuximab vedotin in study SGN35-005 and C25001 and had an ongoing objective response at the time of discontinuation of brentuximab vedotin and subsequently progressed after stopping treatment.
05 October 2018	Provides a treatment option for patients treated in Study C25001 with clinical progression after the Independent Review Board has stopped reviewing scans for the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This study was initially designed as an open-label treatment, multicenter study in subjects on the placebo arm in Study SGN35-005 who experienced progression of HL. In the US only, this study was amended to provide expanded access until approval.

Notes: